Cytori Therapeutics, Inc. Message Board
-
Your brain is half empty bundle. while nobody can blame anyone but themselves for deciding to make an investment in Cytori, who exactly would you blame for the poor execution, broken promises, and patetic balance sheet. Chuckles you never cease to amaze me.
-
Sad but true. This could get uglier
-
Sorry hedge but Cytori is no laughing matter and I have completely lost my sense of humor on anything cytori related.
-
Cytori is dead money and unlikely to see the old high of $8.50 for quite some time. Before there is any type of sustained growth is the PPS, cytori needs to deal with it's frightful balance sheet. Management speaks of the $56 million possibility from Barda but that is a ways off, if it happens at all. The company needs an immediate cash infusion and it looks to me like additional dillution and fundraising through additional issuance of shares will be necessary. That said, would you be a buyer now ? It is a scary thought as to what the price of the secondary will be. i shudder at the thought and get further sick to my stomach. To add on top of that bright news, as management chooses to no longer speculate on when a partnership or milestone payment will happen shareholders are left to twist in the wind like a battered flag. being a shareholder of Cytori is quite an unpleasurable and frustrating experience.
-
hedge not sure why Chuckles or anybody would give your post a thumbs down just stupid.
-
iif this is the right raod we are on then management tshould know whay lies at the end of it so that we don;t hit another dead end,. it's all about execution. that will drive the stock price. investors are content to wait and see and will happily invest when the picture becomes clear,Most large investors are of liek mind.
-
yes jd we misunderstood your postion on Olmpus,
-
hedge your into chuclies head. it's amuzing that there are not 8 people posting but 8 thumbs down, Chuckies adding id's. rotflmao
-
Chuckles , this post definitely deserved your thumbs down . gret back on your meds. in the future if you keep your mouth shut then we won't know your ignorant. time for a new id.lol.
-
great to see you have added another id. truth hurtd you psycho. Go back and read all your posts and give us your spin. Oh wait i'm on ignore. Thank god.
-
That is excellent new. no squeeze but would rather have the sentiment change,much better for the long term. Funding an issue for sure. How many times can you restructure GE,line of credit. If utimately they need to dilute more shure would like to see a raise at $8.50 or a split at $100 as opposed to a nother raise at $2.85
-
James Cytechhio Chuckles or whoever you are today you are an idiot. Cytori mangement told us over a year ago and continued to reiterate that tOlympus was not going to manufacture later term cellution machines. You have ignored this and have been posting how crucial it was to maintain this relationship and it was critical. They were to be our savior. I have told you time after time that Olympus was not in the plans. and so has mangement. It is a non issue and ultmately good for the company but completely contrary to what you have posted forvever. Be silent it was nice. Hope it all hapens. Dead money for awhile, no need to add until they show me something. Still need money. Lot's depends on Barda. Wonder what the shorts think.
-
It's 1:30 pm and shares traded just equaked my holdings in this todate POS. No laughing here. Anxiously awaiting call.
-
Cytori Therapeutics (NASDAQ: CYTX) uses adult adipose-derived (adipose cells refer to fat cells) stem cells for regenerative medicine. The company’s product, Puregraft 850, was approved by the FDA last year in March for use in body contouring. The company is also currently running trials to establish the efficacy of their therapy developed for patients suffering from heart failure due to reduced blood flow.
Cytori was also awarded a contract by BARDA, a division of the U.S. Health and Human Services, worth about $106 million for developing thermal burns and radiation injury treatment. The company’s annual revenue for FY 2012 was $14.5 million. The company, however, is currently operating at a loss and needs a huge jump in revenue to transition to profit.
A HUGE JUMP IN REVENUE AND A GD PARTNERSHIP DEAL.PROMISES PROMISES. -
Yes Who else,Jason Kolbert #1 Shill for Cytori
-
No interest dead money and everyone knows "The art of being Calhouned"
-
Cytori Therapeutics, Inc. Buy
(CYTX – NASDAQ – $2.61)
Earnings Preview
Cytori reports the quarter on May 9 at 5:00pm. The dial-in number is (877) 402-3914. Our focus is currently on the enrollment progress of the PII ATHENA pilot study (N=45), as well as the revenue build-out (with Japan as the leading contributor) and progress on the BARDA contract. We estimate $3.8M in total revenues for the quarter.
ATHENA trial. We expect to receive an update on the number of patients enrolled in the chronic myocardial ischemia (CMI) trial. At last update, nine patients had been treated. Cytori is on track to complete the trial by mid-summer, with data coming six months after the last patient treatment. We believe that Cytori is on a fast track (PMA guidelines) to potentially be the first FDA-approved cardiovascular therapy in the marketplace, potentially giving the company first-mover advantage with an autologous therapy and allogeneic (or better) COGS. We believe these are critical elements in the cell therapy space.
ADVANCE trial. The ADVANCE trial in STEMI has enrolled 15 patients so far. We believe Cytori is not prioritizing the ADVANCE trial and will run enrollment to 25 patients, driving towards an interim analysis to be performed after the first 72 patients. There are multiple goals for ADVANCE, but it is secondary to ATHENA and BARDA.
Let’s not forget about BARDA.BARDA represents a significant opportunity for Cytori to develop great clinical data with commercial value (and a government supply contract as an added incentive), in our opinion. We expect to hear about the progress made toward potentially realizing milestones of $56M.
Cytori has 41 investigator-led studies underway, including a grant-funded ($5 million) male/female urinary incontinence trial in Nagoya, Japan. This trial has the potential to drive an approved and reimbursed indication in Japan. We believe Japan represents a significant market due to its robust appetite for cell therapy.
Valuatio -
idiot, i bought the stock at $3 and sold at $203. My only mistake was not selling all my shares then. I was in the stock for 17 years and traded it and held core position. When company was bought I made a huge profit. We sued because we did not want company sold to BMY as we knew lead compound would be approved and shareholders wanted company to remain independant to capitalize instead of it being stolen for a song and a dance . The drug ipilimimab is the #1 cancer drug for treating melenoma and now other cancers in the BMY stable. That is why. Everu time you posy Chuck you show just how stupid you are. Had to laugh out loud on your provenge post as you quoted a TV commercial that is currently running for Provenge . Your just a fool and a fool if he keeps his mouth shut can keep people from knowing that. Although to this point in your life you have not followed that advise ,you should begin now.
-
clearly chucles you have no knowledge of who i am nor my tolerence . as far as stomach or patience I waited 17 for Medarex. You can google the story to educate yourself, and I surely have more invested here then you in in a year, why not focus on reality skitzo.
-
you must be stupid stupid stupid. seems like nobody has not taken respondsibility for there choice to invest in cytori. i have seen no posts to that effect . that does not change the fact that mangement has performed poorly up to this point in time, history is history mangement has even admitted many mistakes but you won't accept that fact. so now tell us how great things are. we are still here because we believe the science will win out but time waits for no one and competition is fierce.